Actively Recruiting
Comparing Venetoclax, Azacytidine, and Quizartinib Versus Venetoclax and Azacytidine in Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy
Led by PETHEMA Foundation · Updated on 2026-11-04
376
Participants Needed
52
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether adding Quizartinib to the combination of Venetoclax and Azacytidine improves overall survival compared to Venetoclax and Azacytidine alone in adults with newly diagnosed acute myeloid leukemia AML who are not suitable for standard induction chemotherapy due to age, other health conditions, or risk factors. This Phase III trial will randomize participants to compare the two treatment regimens. Participants will be assigned to one of two groups the experimental group will receive Azacytidine as a subcutaneous injection daily on days 1 to 7 of each 28-day cycle, Venetoclax orally daily on days 1 to 7, and Quizartinib orally on days 8 to 21 with dose adjusted by FLT3-ITD mutation status. The standard group will receive Azacytidine daily on days 1 to 7 and Venetoclax daily for 28 days in each 28-day cycle. Treatment continues until disease progression, unacceptable side effects, withdrawal, or other protocol-defined reasons. During the study, participants will have regular clinical visits and follow-up assessments, with survival data collected every three months for two years after the last participant finishes treatment. Researchers will monitor overall survival over four years as the primary outcome, along with event-free survival and complete response rates. Safety and treatment effects will be tracked throughout the study period.
CONDITIONS
Brief Title
Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)
Research Team
P
Pau Montesinos
J
Juan José Lahuerta
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here